SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates

SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

Brinton Vision Announces Publication Highlighting Significant Industry Honors and Clinical Contributions

ST. LOUIS, MO - January 23, 2026 - PRESSADVANTAGE - Brinton Vision today announced the release of its new article, ...
The Clinton Herald

SAVVY SENIOR: How to turn down the volume on tinnitus

Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of “The Savvy Senior” book.
Healio

Anti-VEGF patient assistance programs yield vision gains for underinsured patients

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...
Healio

FDA grants urcosimod 0.05% single-patient use for neuropathic corneal pain

The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with ...
Ophthalmology Times

FDA grants single-patient expanded access for urcosimod in neuropathic corneal pain

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...
Ophthalmology Times

Q&A: What’s in the glaucoma treatment pipeline?

Prostaglandin analogues, such as latanoprost and bimatoprost, are the go-to therapies for glaucoma therapy. They continue to ...